CTOs on the Move


 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

West Virginia United Health System

The West Virginia United Health System (WVUHS) is committed to improving the health of the communities it serves through the delivery of quality, cost-effective health care services and the support of health professional training and research.

NeoChord

NeoChord is a venture backed medical device company that has developed a proprietary device which allows mitral valve repair to be performed on a beating heart through a 2- to 3-inch incision between the ribs in patients with severe mitral valve regurgitation (MR). In contrast, most mitral valve repair procedures are performed through a 3 to 10 inch chest incision (sternotomy) that involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on cardio-pulmonary bypass (CPB).

Avancen

Avancen is a Mount Pleasant, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

The Carolinas Center for Medical Excellence (CCME)

The Carolinas Center for Medical Excellence (CCME) is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.